Nonsteroidal anti-inflammatory drugs after acute myocardial infarction

American Journal of Cardiology

Volumn 83, Issue 8, 1999, Pages 1263-1265

  Sajadieh, Ahmad ^a   Wendelboe, Olav ^a   Hansen, Jørgen Fischer ^a   Mortensen, Leif Spange ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNI C Olof Palmes Allé 38 ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; VERAPAMIL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SAFETY; SURVIVAL RATE; VERAPAMIL;

EID: 0033561164     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00068-5     Document Type: Article

References (18)

1. Ross T. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
2. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Eng J Med. 331:1994;417-424.
3. Morrow D.R., Rifai N., Antman E.M., Weiner D.L., McCabe C.H., Cannon C.P., Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes a TIMI IIA substudy . J Am Coll Cardiol. 31:1998;1460-1465.
4. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
5. Phillips A.N., Neaton J.D., Cook D.G., Grimm R.H., Shaper A.G. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol. 136:1992;59-70.
6. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparantly healthy men. N Engl J Med. 336:1997;973-979.
7. Romson J.L., Hook B.G., Rigot V.H., Schork M.A., Swanson D.P., Lucchesi B.R. The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. Circulation. 66:1982;1002-1011.
8. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol. 66:1990;779-785.
9. Jugdutt B.I. Delayed effects of early infarct-limiting therapies on healing after myocardial infarction. Circulation. 72:1985;907-914.
10. Evans R.G., Val-Mejias J.E., Kulevich J., Fischer V.W., Mueller H.S. Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium effects of ibuprofen and verapamil . Cardiovasc Res. 19:1985;132-138.
11. Clement R., Das D.K., Engelman R.M., Otani H., Bandhyopadhyay D., Hoory S., Antar M., Rousou J.A., Breyer R.H., Prasad M.R. Role of a nonsteroidal anti-inflammatory agent, ibuprofen, in coronary revascularization after acute myocardial infarction. Basic Res Cardiol. 85:1990;55-70.
12. Cannon R.O., Rodriguez E.R., Speir E., Yamaguchi M., Butany J., McManus B.M., Bolli R., Ferrans V.J. Effect of ibuprofen on the healing phase of experimental myocardial infarction in the rat. Am J Cardiol. 55:1985;1609-1613.
13. Jugdutt B.I. Effect of nitroglycerin and ibuprofen on left ventricular topography and rupture threshold during healing after myocardial infarction in the dog. Can J Physiol Pharmacol. 66:1988;385-395.
14. Lal A., Sharma M.L. Failure to reduce experimental myocardial infarct size with ibuprofen pre-treatment in rats. Indian J Physiol Pharmacol. 36:1992;133-134.
15. Jugdutt B.I., Basualdo C.A. Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic postinfarction pericarditis. Influence of other pharmacologic agents during early remodelling. Can J Cardiol. 5:1989;211-221.
16. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 144:1996;537-547.
17. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 97:1998;425-428.
18. Rampart M., Williams T.J. Suppression of inflammatory oedema by ibuprofen involving a mechanism independent of cyclo-oxygenase inhibition. Biochem Pharmacol. 35:1986;581-586.